Samsung finalizes Raypax beta siteKorean PACS firm Samsung has announced that Palo Alto Medical Clinic has agreed to be the beta site for the company’s Raypax PACS product. The clinic will be Samsung’s first U.S. installation of Raypax
Korean PACS firm Samsung has announced that Palo Alto Medical Clinic has agreed to be the beta site for the companys Raypax PACS product. The clinic will be Samsungs first U.S. installation of Raypax since it received 510(k) clearance earlier this year (
PNN
8/99). The system was installed the first week of August, and initially will deal with two modalities, CT and MRI. Samsung, which maintains U.S. operations in San Jose, CA, will work with PAMC to create a version of Raypax that meets the requirements of American radiologists, the company said.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.